NEOADJUVANT PUBLICATIONS & ABSTRACTS
Neoadjuvant data

Evidence / Neoadjuvant
Real World Evidence of MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting
Publication: ASBRS 2025Authors: Thompson et al.Title: Real World Evidence of MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant settingIntroduction:Decisions regarding the extent of axillary surgery in HR+HER2- early-stage breast cancer (EBC) are primarily based on clinical factors, including age, T-stage, and N-stageThe ACOSOG Z00111 trial found Read More
Successful Unconventional Precision Treatment of Inflammatory Hormone Receptor-Positive Breast Cancer Guided by Molecular Profiling
Publication: npj Precision Oncology | (2025) 9:63 Authors: Jailan Elayoubi , Yu Zong & Erich J. Schwartz Title: Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling Abstract: We present a unique case of locally advanced, inflammatory hormone receptor (HR) positive, human epidermal growth Read More
Neoadjuvant HER2-Targeted Therapy Response by BluePrint Gene Expression-Based Molecular Subtyping in Patients with HER2+ Early-Stage Breast Cancer from FLEX
Publication: 19th SGBCC 2025-P201 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce O’Shaughnessy, William Audeh Title: Neoadjuvant HER2-Targeted Therapy Response by BluePrint® Gene Expression-Based Molecular Subtyping in patients with HER2+ Early-Stage Breast Cancer from FLEX Introduction: • Clinical HER2+ (cHER2+) early-stage breast cancer (EBC) accounts Read More
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King
Publication: International Journal of Molecular Sciences 2025, 26, 491 Authors: Rakhshanda Layeequr Rahman, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, and Joyce O’Shaughnessy Title: Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King Abtract: Clinical Read More
MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Source: San Antonio Breast Cancer Symposium® 2024 Authors: Joyce O’Shaughnessy, Priyanka Sharma, Cynthia R C Osborne, Gregory Vidal, Pond Remsen Kelemen, Suzanne Hoekstra, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, FLEX Investigators’ Group Title: MammaPrint® and BluePrint® Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Read More
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers
Publication: Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1553. Authors: Alejandro Rios-Hoyo, Kaitlyn Xiong, Jiawei Dai, Christina Yau, Michal Marczyk, Rolando Garcia-Milian, Denise M Wolf, Laura A Huppert, Rita Nanda, Gillian L Hirst, Erin F Cobain, Laura J van 't Veer, Laura J Esserman, Lajos Pusztai Title: Hormone Receptor Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read More

